A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT04077099

Public ClinicalTrials.gov record NCT04077099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Study identification

NCT ID: NCT04077099
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 231 participants

Conditions and interventions

Conditions

NSCLC

Interventions

REGN5093 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 6, 2020
Primary completion: Apr 21, 2032
Completion: Apr 21, 2032
Last update posted: Jun 16, 2026

2020 – 2032

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Withdrawn
University of California Irvine Medical Center - Bldg 56, RT81, Rm 241	Orange	California	92868	Completed
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	Completed
Moffitt Cancer Center - McKinley Drive	Tampa	Florida	33612	Recruiting
University of Kentucky, Markey Cancer Center Clinical Research Organization	Lexington	Kentucky	40536	Withdrawn
DNU_Massachusetts General Hospital_DNU	Boston	Massachusetts	02114	Withdrawn
Dana Farber Harvard Cancer Center Consortium	Boston	Massachusetts	02215	Completed
Henry Ford Health System	Detroit	Michigan	48202	Withdrawn
Washington University School of Medicine	St Louis	Missouri	63110	Withdrawn
NYU Cancer Institute	New York	New York	10016	Withdrawn
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Completed
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Completed
Duke Cancer Center	Durham	North Carolina	27710	Withdrawn
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Withdrawn
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Withdrawn
University of Pittsburgh UPMC - Clinical Research Services	Pittsburgh	Pennsylvania	15232	Completed
Harold C. Simmons Comprehensive Cancer Center	Dallas	Texas	75235	Withdrawn
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04077099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 16, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04077099 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →